VIATRIS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
VIATRIS INC. (VTRS) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price of $31.79 per share as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $31.79.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $31.94.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $34.22.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $35.68.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $31.79 10-Q · filed 2026-08-06 |
| 2026-03-31 | $31.94 10-Q · filed 2026-05-07 |
| 2025-12-31 | $34.22 10-K · filed 2026-02-26 |
| 2025-09-30 | $35.68 10-Q · filed 2025-11-06 |
| 2025-06-30 | $35.88 10-Q · filed 2025-08-07 |
| 2025-03-31 | $35.54 10-Q · filed 2025-05-08 |
| 2024-12-31 | $35.99 10-K · filed 2025-02-27 |
| 2024-09-30 | $35.99 10-Q · filed 2024-11-07 |
| 2024-06-30 | $36.12 10-Q · filed 2024-08-08 |
| 2024-03-31 | $35.90 10-Q · filed 2024-05-09 |
| 2023-12-31 | $37.53 10-K · filed 2024-02-28 |
| 2023-09-30 | $37.55 10-Q · filed 2023-11-08 |
| 2023-06-30 | $37.31 10-Q · filed 2023-08-07 |
| 2023-03-31 | $37.20 10-Q · filed 2023-05-08 |
| 2022-12-31 | $38.70 10-K · filed 2023-02-27 |
| 2022-09-30 | $38.62 10-Q · filed 2022-11-07 |
| 2022-06-30 | $38.43 10-Q · filed 2022-08-08 |
| 2022-03-31 | $38.21 10-Q · filed 2022-05-09 |
| 2021-12-31 | $37.45 10-K · filed 2022-02-28 |
| 2021-09-30 | $37.40 10-Q · filed 2021-11-08 |
| 2021-06-30 | $37.37 10-Q · filed 2021-08-09 |
| 2021-03-31 | $37.28 10-Q · filed 2021-05-10 |
| 2020-12-31 | $35.65 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |